^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    PY159

    i
    Other names: PY159, PY 159, anti-PI-106
    Associations

    News

    Trials
    Company:
    Foundery Biosciences, ImageneBio
    Drug class:
    TREM1 agonist
    Associations

    News

    Trials
    almost2years
    A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=127, Terminated, Ikena Oncology | Phase classification: P1a/1b --> P1 | N=343 --> 127 | Trial completion date: Dec 2025 --> Aug 2023 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Aug 2023; Sponsor business decision.
    Phase classification • Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • PY159
    over2years
    A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=343, Active, not recruiting, Pionyr Immunotherapeutics Inc. | Recruiting --> Active, not recruiting | Trial completion date: Apr 2023 --> Dec 2025 | Trial primary completion date: Apr 2023 --> Dec 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • PY159
    over4years
    A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=298, Recruiting, Pionyr Immunotherapeutics Inc. | N=216 --> 298 | Trial completion date: Nov 2023 --> Apr 2023 | Trial primary completion date: Nov 2023 --> Apr 2023
    Clinical • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • PD-1 (Programmed cell death 1)
    |
    MSI-H/dMMR
    |
    Keytruda (pembrolizumab) • PY159
    5years
    A Phase 1a/1b First-In-Human (FIH) Study of PY159 in Subjects With Advanced Solid Tumors (clinicaltrials.gov)
    P1a/1b, N=216, Recruiting, Pionyr Immunotherapeutics Inc.
    Clinical • New P1 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HR positive • MSI-H/dMMR • HER-2 negative
    |
    Keytruda (pembrolizumab) • PY159